GW Pharmaceuticals Plc has appointed Tom Lynch, previously a chief executive and now non-executive director of Amarin Corporation Plc, as a non-executive director with immediate effect. Mr Lynch replaces Hans Schram, who is retiring. Besides leading Amarin, Mr Lynch was an executive at Elan Corporation Plc from 1993 to 2004 and was responsible for that company’s acquisition of Athena Neurosciences Inc in March 1996 which gave Elan research assets in Alzheimer’s disease and auto-immune diseases. In his new role at GW, Mr Lynch will chair the audit committee and sit on the remuneration committee.
Copyright 2010 Evernow Publishing Ltd